Royan Institute
Iran
- Country
- Iran
- Ownership
- Private
- Established
- 1991-01-01
- Employees
- -
- Market Cap
- -
Clinical Trials
156
Active:0
Completed:118
Trial Phases
6 Phases
Early Phase 1:1
Phase 1:57
Phase 2:21
+3 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (155 trials with phase data)• Click on a phase to view related trials
Phase 1
57 (36.8%)Not Applicable
35 (22.6%)Phase 3
34 (21.9%)Phase 2
21 (13.5%)Phase 4
7 (4.5%)Early Phase 1
1 (0.6%)Intra-ovarian Injection of MSC-EVs in Idiopathic Premature Ovarian Failure
Phase 1
Recruiting
- Conditions
- Premature Ovarian Failure
- First Posted Date
- 2024-01-11
- Last Posted Date
- 2024-01-11
- Lead Sponsor
- Royan Institute
- Target Recruit Count
- 10
- Registration Number
- NCT06202547
- Locations
- 🇮🇷
Royan Institute, Tehran, Iran, Islamic Republic of
Dual Ovarian Stimulation (Duostim) and Shanghai Protocols in Poor Ovarian Responders
Phase 3
Completed
- Conditions
- Assisted Reproductive Techniques
- First Posted Date
- 2024-01-10
- Last Posted Date
- 2024-01-10
- Lead Sponsor
- Royan Institute
- Target Recruit Count
- 116
- Registration Number
- NCT06199960
- Locations
- 🇮🇷
Royan Institute, Tehran, Iran, Islamic Republic of
Cinnamon and COH in PCOS Women Underdoing IVF/ICSI Cycles
Not Applicable
Recruiting
- Conditions
- Polycystic Ovary Syndrome
- First Posted Date
- 2024-01-10
- Last Posted Date
- 2024-01-10
- Lead Sponsor
- Royan Institute
- Target Recruit Count
- 80
- Registration Number
- NCT06199024
- Locations
- 🇮🇷
Royan Institute, Tehran, Iran, Islamic Republic of
NAC Effect on Infertile Women With Endometrioma
Phase 3
- Conditions
- Female InfertilityEndometriomaStress Oxidative
- Interventions
- Drug: placebo
- First Posted Date
- 2022-07-15
- Last Posted Date
- 2022-07-15
- Lead Sponsor
- Royan Institute
- Target Recruit Count
- 140
- Registration Number
- NCT05460858
- Locations
- 🇮🇷
Royan Institute, Tehran, Iran, Islamic Republic of
Nk Cell Therapy for Recurrent Glioblastoma Multiform Patients
Phase 1
- Conditions
- Glioblastoma MultiformRecurrent Glioblastoma
- First Posted Date
- 2021-11-04
- Last Posted Date
- 2021-11-22
- Lead Sponsor
- Royan Institute
- Target Recruit Count
- 5
- Registration Number
- NCT05108012
- Locations
- 🇮🇷
Royan institute, Tehran, Iran, Islamic Republic of
- Prev
- 1
- 2
- 3
- 4
- 5
- 19
- Next
News
No news found